Navidea begins patient enrolment in paediatric trial of lymphoseek to treat solid tumours

Ireland-based Navidea Biopharmaceuticals has started patient enrolment in a clinical trial comparing Lymphoseek (technetium Tc 99m tilmanocept) injection and vital blue dye (VBD) in children with melanoma, rhabdomyosarcoma, or other solid tumours.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news